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The maturation of biopharmaceutical process understanding and technical advances have paved the way 
towards the commercial application of continuous bioprocesses. In particular, mammalian cell perfusion cultures 
have received manifold attention for cell expansion in the N-1 stage or the continuous production in end-to-end 
biomanufacturing processes. Perfusion processes uniquely offer both optimal cellular and/or consistent product 
environment. However, their inherent complexity in equipment and operation demands thorough process 
characterization and development.  
 
In this presentation, development efforts to build on the potential of perfusion processes and challenges during 
commercial implementation are shared. In a first case study, in depth equipment characterization resulted in a 
robust and versatile perfusion design1. Stable operation and short bioreactor residence time allowed the 
continuous harvest of the target protein with constant quality characteristics at lab scale2. Characteristic times 
for the adaption of cell metabolism and product quality to the constant operation were revealed. The potential of 
perfusion cultures to distinctively modulate towards a desired quality profile and benefits of their integration to a 
continuous downstream cascade are demonstrated3.  
 
The second part extends on the potential of perfusion to generate an optimal environment for cell growth. Its 
utilization for the generation of high bioreactor inoculation densities has successfully enabled overall 
manufacturing process intensification. Challenges of the commercial N-1 perfusion process implementation and 
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